SK Biopharmaceuticals Statistics
Total Valuation
KRX:326030 has a market cap or net worth of KRW 8.21 trillion. The enterprise value is 8.09 trillion.
Market Cap | 8.21T |
Enterprise Value | 8.09T |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
Earnings Date | May 9, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
KRX:326030 has 78.31 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 78.31M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.02% |
Owned by Institutions (%) | 12.99% |
Float | 28.06M |
Valuation Ratios
The trailing PE ratio is 34.09 and the forward PE ratio is 55.85.
PE Ratio | 34.09 |
Forward PE | 55.85 |
PS Ratio | 14.99 |
PB Ratio | 14.30 |
P/TBV Ratio | 15.32 |
P/FCF Ratio | 87.77 |
P/OCF Ratio | 86.48 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 98.10, with an EV/FCF ratio of 86.57.
EV / Earnings | 33.63 |
EV / Sales | 14.78 |
EV / EBITDA | 98.10 |
EV / EBIT | 124.37 |
EV / FCF | 86.57 |
Financial Position
The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.32.
Current Ratio | 1.64 |
Quick Ratio | 1.26 |
Debt / Equity | 0.32 |
Debt / EBITDA | 1.62 |
Debt / FCF | 1.97 |
Interest Coverage | 9.02 |
Financial Efficiency
Return on equity (ROE) is 50.72% and return on invested capital (ROIC) is 9.58%.
Return on Equity (ROE) | 50.72% |
Return on Assets (ROA) | 6.84% |
Return on Invested Capital (ROIC) | 9.58% |
Return on Capital Employed (ROCE) | 15.04% |
Revenue Per Employee | 2.27B |
Profits Per Employee | 998.91M |
Employee Count | 241 |
Asset Turnover | 0.62 |
Inventory Turnover | 0.40 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.86% in the last 52 weeks. The beta is 0.93, so KRX:326030's price volatility has been similar to the market average.
Beta (5Y) | 0.93 |
52-Week Price Change | +29.86% |
50-Day Moving Average | 109,684.00 |
200-Day Moving Average | 104,554.50 |
Relative Strength Index (RSI) | 51.80 |
Average Volume (20 Days) | 124,115 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:326030 had revenue of KRW 547.60 billion and earned 240.74 billion in profits. Earnings per share was 3,074.04.
Revenue | 547.60B |
Gross Profit | 504.50B |
Operating Income | 96.34B |
Pretax Income | 72.60B |
Net Income | 240.74B |
EBITDA | 113.77B |
EBIT | 96.34B |
Earnings Per Share (EPS) | 3,074.04 |
Balance Sheet
The company has 324.49 billion in cash and 184.48 billion in debt, giving a net cash position of 140.01 billion or 1,787.78 per share.
Cash & Cash Equivalents | 324.49B |
Total Debt | 184.48B |
Net Cash | 140.01B |
Net Cash Per Share | 1,787.78 |
Equity (Book Value) | 573.98B |
Book Value Per Share | 6,975.49 |
Working Capital | 255.10B |
Cash Flow
In the last 12 months, operating cash flow was 94.90 billion and capital expenditures -1.40 billion, giving a free cash flow of 93.50 billion.
Operating Cash Flow | 94.90B |
Capital Expenditures | -1.40B |
Free Cash Flow | 93.50B |
FCF Per Share | 1,193.98 |
Margins
Gross margin is 92.13%, with operating and profit margins of 17.59% and 43.96%.
Gross Margin | 92.13% |
Operating Margin | 17.59% |
Pretax Margin | 13.26% |
Profit Margin | 43.96% |
EBITDA Margin | 20.78% |
EBIT Margin | 17.59% |
FCF Margin | 17.08% |
Dividends & Yields
KRX:326030 does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | 2.93% |
FCF Yield | 1.14% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
KRX:326030 has an Altman Z-Score of 9.97.
Altman Z-Score | 9.97 |
Piotroski F-Score | n/a |